Gradual Vs. Rapid Buprenorphine Detoxification - 2
Phase 1
Completed
- Conditions
- Opioid-Related Disorders
- Registration Number
- NCT00000220
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to determine an optimal detoxification dose reduction schedule with buprenorphine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug use Retention Observed withdrawal rating Opioid agonist rating Opioid antagonist rating
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie buprenorphine's efficacy in opioid detoxification?
How does gradual buprenorphine detoxification compare to rapid protocols in managing opioid-related disorders?
Are there specific biomarkers that predict successful outcomes in buprenorphine detoxification schedules?
What are the known adverse events associated with buprenorphine detoxification and how are they managed?
What combination therapies or alternative opioid antagonists have been explored alongside buprenorphine for detoxification?
Trial Locations
- Locations (1)
Treatment Research Center
🇺🇸Burlington, Vermont, United States
Treatment Research Center🇺🇸Burlington, Vermont, United States